GRNA Stock Analysis
GR
Uncovered
Greenlight Biosciences Holdings PBC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.045
Dividend yield
—
Shares outstanding
151.55 B
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Medford, Massachusetts. The company went IPO on 2021-01-14. The firm is focused on Ribonucleic acid (RNA) research, design, and manufacturing for human, animal, and plant health. The firm has developed technology to create high-performing, natural ribonucleic acid (RNA) products to address global sustainability challenges and promote healthier plants, foods, and people. The firm is engaged in the cell-free biomanufacturing platform. This platform enables the making of complex biological molecules nucleic acids, peptides, carbohydrates, and many others which allows manufacturing products at a lower cost than traditional methods using fermentation. The platform is used to develop and commercialize products. The firm's pipeline for plant and animal health includes Colorado potato beetle, Botrytis cinerea, Varroa mites, Fungicides, Grapevine powdery mildew, Fusarium Head Blight (FHB), Lepidoptera, and Powdery mildew.